Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
2,210
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis

Jashin J. Wua Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1722-1892View further author information
ORCID Icon,
Ching An Wangb Real-World Analytics & Data Science (RADS), CORDS-CIF for Cardiovascular, Immunology and Fibrosis, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Greeta Jobsonc Offshore Delivery, Mu Sigma, Bangalore, IndiaView further author information
,
David Davidsond Immunology and Fibrosis, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Samaneh Kaliraie Worldwide HEOR – US Market, Immunology, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Julia Zhub Real-World Analytics & Data Science (RADS), CORDS-CIF for Cardiovascular, Immunology and Fibrosis, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Manasi Suryavanshif HEOR Markets Department, Bristol Myers Squibb, Princeton, NJ, USAView further author information
,
Mayank Mittalc Offshore Delivery, Mu Sigma, Bangalore, IndiaView further author information
,
Vardhaman Patele Worldwide HEOR – US Market, Immunology, Bristol Myers Squibb, Princeton, NJ, USAView further author information
&
Lauren Seigele Worldwide HEOR – US Market, Immunology, Bristol Myers Squibb, Princeton, NJ, USAView further author information
 show all
Article: 2177095 | Received 22 Nov 2022, Accepted 31 Jan 2023, Published online: 15 Feb 2023

References

  • Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease. Front Med (Lausanne). 2021;8:743180.
  • Global Report on Psoriasis. Switzerland: World Health Organization; 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis?sequence=1. Accessed: February 6, 2023.
  • Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470.
  • Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
  • Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946.
  • Liu J, Thatiparthi A, Martin A, et al. Prevalence of psoriasis among adults in the US 2009–2010 and 2013–2014 National Health and Nutrition Examination Surveys. J Am Acad Dermatol. 2021;84(3):767–769.
  • Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
  • Wu JJ, Pelletier C, Ung B, et al. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. J Comp Eff Res. 2020;9(11):767–779.
  • Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, et al. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther. 2021;11(6):2107–2121.
  • Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97.
  • Kaplan DL, Ung BL, Pelletier C, et al. Switch rates and total cost of care associated with apremilast and biologic therapies in biologic-naive patients with plaque psoriasis. Clinicoecon Outcomes Res. 2020;12:369–377.
  • Wu JJ, Pelletier C, Ung B, et al. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. J Med Econ. 2019;22(4):365–371.
  • Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the introduction of combination therapy (rescue therapy): data from a multicenter real-life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals (Basel). 2022;15(1):95.
  • Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.